The Relative Strength (RS) Rating for Intra-Cellular Therapies stock entered a new percentile Thursday, with a rise from 75 to 87.
This unique rating tracks technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the last 52 weeks matches up against the rest of the market.
History shows that the stocks that go on to make the biggest gains often have an RS Rating north of 80 as they begin their biggest price moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
Is Intra-Cellular Therapies Stock A Buy?
The IBD 50 stock is building a cup without handle with an 84.89 entry. See if it can clear the breakout price in heavy volume. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The biotech company showed 0% earnings growth in the latest quarterly report, while sales growth came in at 52%.
Intra-Cellular Therapies stock earns the No. 29 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and United Therapeutics are among the top 5 highly rated stocks within the group.
